Home » Newsletters » BioWorld Science

BioWorld Science

April 5, 2016

View Archived Issues

Researchers investigate Nampt inhibitors without CYP2C9 inhibitory effects

PTC Therapeutics presents antibacterial compounds

First-in-human phase I results for the tuberculosis vaccine MVA85A-IMX313

Shire discloses dopamine transporter inhibitors

Shanghai Institute of Organic Chemistry patents indoleamine dioxygenase inhibitors

Proximagen Group presents amine oxidase inhibitors

SIMM, Suzhou Vigonvita Life Sciences and Topharman Shanghai develop antiepileptic compounds

Novartis divulges c-Raf inhibitors

Janssen files application for ibrutinib in Japan

Gilead Sciences acquires Nimbus Therapeutics' ACC inhibitor program

Single-dose and preservative-free formulation of Makena launched in the U.S.

Topical formulation of pritelivir enters phase I clinical testing

Portola and Daiichi Sankyo to develop andexanet alfa with edoxaban in Japan

Second phase II study of NP-001 will enroll patients using biomarker for enriched selection

Boehringer Ingelheim and Kyoto University to investigate new drugs for sensorineural hearing loss

Nerviano Medical Sciences licenses drug-linker technology to Oxford Biotherapeutics

Intrexon creates joint venture to develop treatment for type 1 diabetes

Intec Pharma enrolls first patient in pivotal phase III Parkinson's trial

Multiple sclerosis vaccine well tolerated in phase II study

MJFF awards grant to VCU for Parkinson's disease drug trial

Portable electronic nose shows promise for cancer diagnosis

FDA approves Gilead's Descovy for the treatment of HIV

Silence Therapeutics presents data from Atu-027-I-02 clinical trial

JAK2 shows promise as a prognostic biomarker in NPC

Acucela and UoM announce agreement for the development of an optogenetic gene therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...